

## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/680,228	10/06/2000	John Albert Ellis	454313-2340.2	1613
20999	7590 09/16/2002			
FROMMER LAWRENCE & HAUG			EXAMINER	
745 FIFTH AV NEW YORK,	VENUE- 10TH FL. NY 10151		FOLEY, SHANON A	
			ART UNIT	PAPER NUMBER
			1648	10
			DATE MAILED: 09/16/2002	

Please find below and/or attached an Office communication concerning this application or proceeding.

•						
Advisory Action		Application No.	Applicant(s)			
		09/680,228	ELLIS ET AL.			
		Examiner	Art Unit			
		Shanon Foley	1648			
The MAIL	ING DATE of this communication appe	ars on the cover sheet with the o	correspondence address			
Therefore, further a final rejection under condition for alloward	25 July 2002 FAILS TO PLACE TH ction by the applicant is required to a 37 CFR 1.113 may only be either: (once; (2) a timely filed Notice of Appein compliance with 37 CFR 1.114.	void abandonment of this appli 1) a timely filed amendment whi	cation. A proper reply to a ich places the application in			
	PERIOD FOR RE	EPLY [check either a) or b)]				
b) The period for event, howeve ONLY CHECK 706.07(f). Extensions of time m have been filed is the date 37 CFR 1.17(a) is calcula (b) above, if checked. An earned patent term adjust	reply expiresmonths from the mailing are reply expires on: (1) the mailing date of this Adver, will the statutory period for reply expire later the KITHIS BOX WHEN THE FIRST REPLY WAS may be obtained under 37 CFR 1.136(a). The date for purposes of determining the period of extendated from: (1) the expiration date of the shortened by reply received by the Office later than three moment. See 37 CFR 1.704(b).	visory Action, or (2) the date set forth in the an SIX MONTHS from the mailing date of FILED WITHIN TWO MONTHS OF THe at the on which the petition under 37 CFR 1, sion and the corresponding amount of the distatutory period for reply originally set in on the after the mailing date of the final rejection.	of the final rejection.  E FINAL REJECTION. See MPEP  136(a) and the appropriate extension fee ender the appropriate extension fee under the final Office action; or (2) as set forth in ection, even if timely filed, may reduce any			
	Appeal was filed on Appellant' 2(a), or any extension thereof (37 CF					
2. The proposed	d amendment(s) will not be entered b	ecause:				
(a) 🗌 they rais	(a) ☐ they raise new issues that would require further consideration and/or search (see NOTE below);					
(b) 🗌 they rais	e the issue of new matter (see Note	below);				
· •	not deemed to place the application or appeal; and/or	in better form for appeal by ma	terially reducing or simplifying the			
(d) 🗌 they pre	esent additional claims without cance	ling a corresponding number of	finally rejected claims.			
NOTE:	·					
3. Applicant's re	ply has overcome the following rejec	etion(s):				
	sed or amended claim(s) would e non-allowable claim(s).	d be allowable if submitted in a	separate, timely filed amendment			
	davit, b)□ exhibit, or c)⊠ request fon condition for allowance because: <u>S</u>		sidered but does NOT place the			
	or exhibit will NOT be considered be Examiner in the final rejection.	cause it is not directed SOLELY	to issues which were newly			
7. For purposes explanation	of Appeal, the proposed amendment of how the new or amended claims w	t(s) a)□ will not be entered or l ould be rejected is provided be	o)⊠ will be entered and an low or appended.			
The status of	the claim(s) is (or will be) as follows	:	÷ .			
Claim(s) allo	owed:		·			
	ected to:					
	ected: <u>1,2,17-19,21,23-28,31,32,43-60,6</u>	62 and 63.				
, , ,	ndrawn from consideration:					
	d drawing correction filed on is	s a) approved or b) disap	proved by the Examiner.			
	Note the attached Information Disclosure Statement(s)( PTO-1449) Paper No(s)					

U.S. Patent and Trademark Office

10.⊠ Other: <u>See Continuation Sheet</u>

Continuation of 5. does NOT place the application in condition for allowance because: The proposed amendment does not obviate the 112, second paragraph rejections because it remains unclear which of the 13 PCV-2 polypeptides would be considered antigenic. The proposed amendment also does not obviate the 112, first paragraph enablement rejection because although the claims have been amended to recite reducing viral load, there is no support in the disclosure or the declaration for lowering viral titer with a vector encodin a PCV-2 polypeptide for reasons of record.

Continuation of 10. Other: The Information Disclosure Statement (PTO-1449) submitted with paper no. 16 has not been considered because it was not accompanied by the proper fee under 37 CFR 1.17(p) and a statement required under 37 CFR 1.97(e).

JAMES HOUSEL

SUPERVISORY PATENT EXAMINER TECHNOLOGY CENTER 1600